Effects of combined exercise on quality of life for colorectal cancer patients undergoing chemotherapy
Official title: Effects of Exercise Training on Health-related Quality of Life in Patients With Unresectable Metastatic Colorectal Cancer: A Multi-center Randomized Controlled Trial
Run by Copenhagen University Hospital, Rigshospitalet · NCT06938971 · Data updated 2026-11-12
This study tests if an 18-week exercise program can improve the quality of life for colorectal cancer patients who are receiving chemotherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Copenhagen University Hospital, Rigshospitalet Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 4 sites (Copenhagen and 3 other locations) |
| Status | Recruiting |
| Started | May 16, 2025 |
| Main results expected | May 1, 2027 |
| Study ends | May 1, 2030 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT06938971 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older scheduled for chemotherapy for unresectable metastatic colorectal cancer.
✕Probably not a fit
Patients who are pregnant, have a life expectancy of less than six months, or have contraindications to exercise will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial aims to evaluate the impact of an 18-week structured exercise program on the health-related quality of life of patients with unresectable metastatic colorectal cancer undergoing first-line chemotherapy. Participants will be randomly assigned to either the exercise intervention group or a control group. The study focuses on assessing how physical activity can improve overall well-being during cancer treatment. The exercise regimen includes both resistance and aerobic training tailored to the patients' capabilities.
Why it matters
Potential benefit: If successful, this study could enhance the quality of life for patients undergoing chemotherapy for metastatic colorectal cancer.
How similar studies have gone: Other studies have shown positive outcomes with exercise interventions in cancer patients, suggesting this approach may be beneficial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: \- Adults (≥18 years of age) schduled to undergo first-line chemotherapy for the treatment of metastatic colorectal cancer. Exclusion criteria : * Pregnancy. * A life expectancy of \< 6 months. * Absolute contraindications to maximal exercise, as per the recommendations by the Danish Society of Cardiology. * ECOG (Eastern Cooperative Oncology Group) performance status \> 2. * Inability to understand the Danish or English language. * Engagement in structured moderate-to-high aerobic exercise training for \>30 min \>1 times/week for the past 3 months at the time of inclusion.
Where it's running
-
Centre for Physical Activity Research, Copenhagen Univerisity Hospital - Rigshospitalet
Copenhagen, Denmark Recruiting -
Herlev and Gentofte Hospital
Herlev, Denmark Recruiting -
North Zealand University Hospital, Hillerød
Hillerød, Denmark Recruiting -
Zealand University Hospital, Roskilde
Roskilde, Denmark Recruiting
Study contacts
- Study coordinator: Casper Simonsen, Phd
- Email: casper.simonsen@regionh.dk
- Phone: +45 35 45 76 41
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Continuing cetuximab after first progression for metastatic colorectal cancer
This study will test whether keeping cetuximab while switching the chemotherapy backbone helps adults with RAS/BRAF wild‑type metastatic colorectal cancer whose disease progressed after first‑line anti‑EGFR therapy.
-
µCAN diagnostic to pick the best drugs for metastatic colorectal cancer
This will test whether the µCAN lab test can identify the best drugs for people with metastatic colorectal cancer who are about to start a new line of treatment.
-
Combining hydroxychloroquine with chemotherapy for advanced colorectal cancer
This study is testing if adding hydroxychloroquine to standard chemotherapy can help people with advanced colorectal cancer live longer and feel better.
-
Testing a new treatment for metastatic colorectal cancer
This study is testing a new treatment called arfolitixorin for people with metastatic colorectal cancer to see if it works better than the usual therapy.
-
Evaluating Fruquintinib for Metastatic Colorectal Cancer
This study is testing how well Fruquintinib works for people with metastatic colorectal cancer who have already tried other treatments, to see how it affects their survival and quality of life.
-
Registry for patients with advanced metastatic colorectal cancer
This study is collecting information from patients with advanced colorectal cancer who have tried different treatments to see how well they are doing and to help improve future care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.